LXRX vs MELI · rev $21.8M vs P/E 43, rev $19.01B
Lexicon Pharmaceuticals Inc (LXRX) versus MercadoLibre Inc. (MELI) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
Latest reported MELI revenue for 2026-06-30 was $19.01B. Net income was $883.0M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
LXRX currently screens at market cap $327.2M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Not investment advice. Open the LXRX and MELI stock pages for the full models.
Not investment advice.